SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD. Pioglitazone is the only drug recommended in diabetes patients with b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Diabetes
Autors principals: Raj, Henith, Durgia, Harsh, Palui, Rajan, Kamalanathan, Sadishkumar, Selvarajan, Sandhiya, Kar, Sitanshu Sekhar, Sahoo, Jayaprakash
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2019
Matèries:
Systematic Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6379733/
https://ncbi.nlm.nih.gov/pubmed/30788048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v10.i2.114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars